Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: aPCC Clear all
Completed Phase 3 Interventional Results available

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

NCT02740335
View directory record Official record
Conditions
Significant Bleeding Risk
Interventions
Octaplex, Beriplex P/N (Kcentra)
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII, factor IX, factor VIII
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 21, 2026, 2:20 PM EDT
Recruiting No phase listed Observational

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

NCT06008938
View directory record Official record
Conditions
Hemophilia B
Interventions
HEMGENIX, Factor IX (FIX)
Genetic · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2043
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Early Phase 1 Interventional

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

NCT03272568
View directory record Official record
Conditions
Hemophilia, Menstrual Flow Excessive
Interventions
Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

NCT03569891
View directory record Official record
Conditions
Hemophilia B
Interventions
AAV5-hFIXco-Padua, Factor IX (FIX)
Genetic · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

NCT00851721
View directory record Official record
Conditions
Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
Interventions
Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
4 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

NCT02234310
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Up to 17 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
11
States / cities
Sacramento, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 21, 2026, 2:20 PM EDT
Completed No phase listed Observational

Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass

NCT01352143
View directory record Official record
Conditions
Cardiopulmonary Bypass
Interventions
Recombinant activated factor VII, Prothrombin Complex Concentrate
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 21, 2026, 2:20 PM EDT
Not yet recruiting Phase 4 Interventional

Prothrombin Complex Concentrate (PCC)

NCT07881393
View directory record Official record
Conditions
Cardiopulmonary Bypass
Interventions
Four Factor Prothrombin Complex Concentrate, ROTEM (Rotational Thromboelastometry) analyzer (TEM International GmbH)
Drug · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 2:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Factor IX Gene Therapy Study (FIX-GT)

NCT03369444
View directory record Official record
Conditions
Hemophilia B
Interventions
FLT180a
Biological
Lead sponsor
University College, London
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 21, 2026, 2:20 PM EDT
Completed No phase listed Observational

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

NCT02190149
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant])
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
13 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

NCT03549871
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran, BPA prophylaxis, Factor (FVIII or FIX) prophylaxis
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 1 Interventional

Phase I/IIa Study of FIXFc in Hemophilia B Patients

NCT00716716
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

NCT00618098
View directory record Official record
Conditions
Reversal of Anticoagulant Treatment
Interventions
Octaplex (human prothrombin complex concentrate), Fresh frozen plasma
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

NCT00221195
View directory record Official record
Conditions
Hemophilia A With Inhibitors
Interventions
activated prothrombin complex concentrate (FEIBA)
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
24 Months and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 21, 2026, 2:20 PM EDT
Recruiting Phase 4 Interventional

Hemlibra in Mild Hemophilia A

NCT04567511
View directory record Official record
Conditions
Factor VIII Deficiency, Congenital
Interventions
Emicizumab
Drug
Lead sponsor
Indiana Hemophilia &Thrombosis Center, Inc.
Other
Eligibility
5 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 21, 2026, 2:20 PM EDT
Terminated No phase listed Observational

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

NCT02392156
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
rFVIIIFc, rFIXFc, non-Fc FVIII replacement products, non-Fc FIX replacement products
Biological · Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Los Angeles, California • East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

NCT02557672
View directory record Official record
Conditions
Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex Concentrates, Fresh Frozen Plasma
Interventions
Prothrombin complex concentrate (Human), Fresh frozen plasma (FFP)
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 21, 2026, 2:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

NCT05164471
View directory record Official record
Conditions
Hemophilia B
Interventions
verbrinacogene setparvovec
Genetic
Lead sponsor
Spur Therapeutics
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Results available

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

NCT03064035
View directory record Official record
Conditions
Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
Interventions
4-factor prothrombin complex concentrate (4FPCC)
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 125 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

NCT05523297
View directory record Official record
Conditions
Bleeding Cardiac Surgery Patients
Interventions
Octaplex, Frozen Plasma Product, Human
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Dose Confirmation Trial of AAV5-hFIXco-Padua

NCT03489291
View directory record Official record
Conditions
Hemophilia B
Interventions
AAV5-hFIXco-Padua (AMT-061)
Genetic
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

NCT01425723
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

NCT00364182
View directory record Official record
Conditions
Hemophilia B
Interventions
Recombinant Coagulation Factor IX (BeneFIX)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
Phoenix, Arizona • Chicago, Illinois • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 21, 2026, 2:20 PM EDT